- idUS
- Listar por autor
Listar por autor "Rojo, F."
Mostrando ítems 1-3 de 3
-
Artículo
Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours
Garrido, P.; Hladun, R.; Álava Casado, Enrique de; Álvarez, R.; Bautista, F.; López-Ríos, F.; Colomer, R.; Rojo, F. (Springer, 2021-02-23)The recent identification of rearrangements of neurotrophic tyrosine receptor kinase (NTRK) genes and the development ...
-
Artículo
Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study
Cruz Merino, Luis de la; Gion, M.; Cruz, J.; Alonso-Romero, J. L.; Quiroga, V.; Moreno, F.; Jiménez Cortegana, Carlos; Sánchez Margalet, Víctor; Rojo, F. (BMC, 2023)Background: We evaluated a new chemoimmunotherapy combination based on the anti-PD1 monoclonal antibody pembrolizumab and ...
-
Artículo
Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER)
Albanell, J.; Martínez, M. T.; Ramos, M.; O´Connor, M.; Cruz Merino, Luis de la; Santaballa, A.; Rojo, F. (ELSEVIER SCI LTD, 2022)Background The potential benefit of adding palbociclib to fulvestrant as first-line treatment in hormone receptor ...